Anadis (ASX: ANX; OTC: ANDIY) announced today its commercialization of a new product, BioGard(TM), intended to maintain gastrointestinal and immune system health. The specific formulation may be of particular clinical benefit in persons undergoing antiretroviral therapy for HIV/AIDS.

Anadis Limited (ASX: ANX), an Australian-based biotechnology company focused on milk derived polyclonal antibodies and other milk-derived bioactives, announced today that it had signed a final agreement with ImmuCell Corporation (NASDAQ Capital Market: ICCC), a biotechnology company headquartered in Portland, Maine, USA.

Anadis Limited (ASX:ANX; OTC: ANDIY), today announced major progress in its anti-flu virus antibody program.

Hadasit and Anadis, Ltd. (ASX:ANX) announced today their intention to form a new joint venture company tentatively called Immuron. The mandate of the new company is to develop a new line of therapeutic products for the treatment of several inflammatory diseases, infectious diseases and cancers.

Anadis Limited (ASX:ANX), a biotechnology company focused on the use of polyclonal antibodies for human health, has announced a successful conclusion to a private placement, raising US$600,000 from U.S. and Australian investors.